Medical Condition News

RSS

NanoPass signs license agreement for supply of MicronJet600 device to Circassia

NanoPass Technologies Ltd., a pioneer in intradermal delivery solutions for vaccines, announced today that it has entered into a license agreement for the supply of MicronJet600, its microneedle delivery device, to Circassia Pharmaceuticals plc. (Oxford, UK), a specialty biopharmaceutical company focused on the allergy market.

6 May 2015

JDRF, Lilly partner to make life better for people with type 1 diabetes

JDRF, the leading global organization funding type 1 diabetes (T1D) research, and Eli Lilly and Company, a global leader in diabetes care announced a two-year partnership that will provide $1.8 Million in support of JDRF's mission to improving the lives of people with T1D.

6 May 2015

Elekta striving to build radiation therapy infrastructures and save lives of cancer patients in Africa

In Africa, cancer kills more people than HIV/AIDS, malaria and tuberculosis combined. Approximately 40 percent of cancer cases can be prevented and 40 percent can be cured with the right treatment. Together with Elekta, ministries of health in almost a dozen African nations are working to build up their radiation therapy infrastructures and save lives.

From Elekta 6 May 2015

CCM and MD Anderson partner to improve cancer care in China, Singapore

Concord Medical Services Holdings Limited, a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, announced today that it has signed a multi-year strategic development agreement with The University of Texas MD Anderson Cancer Center, an internationally renowned cancer research, treatment and education center.

6 May 2015

Researchers compile new genomic interactions catalogue

New clues about diseases like inflammatory bowel disorder may be found thanks to a new genomic interactions catalogue by a group of researchers in Japan and the United Kingdom. This research will be published on May 4, 2015 in Nature Genetics.

6 May 2015

AbbVie's venetoclax granted FDA Breakthrough Therapy Designation for CLL patients with 17p deletion

AbbVie today announced its investigational medicine venetoclax, an inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, has been granted Breakthrough Therapy Designation by the FDA for the treatment of chronic lymphocytic leukemia (CLL) in previously treated (relapsed/refractory) patients with the 17p deletion genetic mutation.

6 May 2015

Partners congratulate researchers on forming new biotechnology company

The Children's Hospital of Eastern Ontario, The Ottawa Hospital, the University of Ottawa and McMaster University congratulate its researchers on forming Turnstone Biologics Inc., a biotechnology company focused on developing new treatments for cancer that harness the patient's own immune system.

6 May 2015

Luxembourg biologists provide complete image of human 'miRNome' in blood samples

In an elaborate study, biologists of the University of Luxembourg have found out that small molecules named microRNAs are, against many hopes, not yet suitable for early diagnosis of skin cancer, as well as supposedly for other types of cancer, in blood samples. For the first time they analysed all microRNAs in the serum of healthy people and thus provided a first complete image of the human "miRNome" in blood samples, in reference to the better-known "genome".

6 May 2015

Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of gastric cancers

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted an Orphan Drug Designation (ODD) for its lead product candidate, REOLYSIN, for the treatment of gastric cancers.

6 May 2015

Weston Park Hospital offers two cutting-edge treatments for rare cancer tumours, prostate cancer

TWO cutting-edge cancer treatments using targeted radioactive therapy injections to destroy cancer cells are now being offered to patients with rare neuroendocrine tumours and patients with prostate cancer at Weston Park Hospital.

6 May 2015

First patient receives new 'resistance-busting' experimental skin cancer drug

A patient has become the first to receive a new 'resistance-busting' experimental skin cancer drug with the launch of a phase I clinical trial. The patient has received a new panRAF inhibitor - a new type of drug under development to address the problem of drug resistance in advanced skin cancer and a number of other cancer types.

6 May 2015

Scientists identify mechanism that explains how some stem cells get new identity

Scientists at the University of Copenhagen have identified one mechanism that explains how some stem cells choose to become a given cell type: the cells combine specific sets of proteins at precise positions along the DNA. When these particular groups of proteins are combined, the gates are opened so that certain groups of genes can now be used, giving the cells a new identity.

6 May 2015

Automated PoCyton cytometer effective for counting cancer cells

Biological and medical scientists have been using flow cytometry to count cancer cells for the past 40 years. But the large instruments are expensive and can only be operated by trained personnel. By contrast the PoCyton cytometer developed by Fraunhofer researchers is cheap to produce, no bigger than a shoebox, and automated.

6 May 2015

Diabetic neuropathy highly prevalent among diabetic patients in Romania

A survey of 25,000 Romanians with diabetes has revealed that diabetic neuropathy (DN), a complication of diabetes, is highly prevalent in these patients, even in the absence of a diagnostic, and has an important impact on patients' quality of life.

6 May 2015

Zetz Family PCRF, Johns Hopkins Medicine partner for pancreatic cancer research

According to a study done by the Pancreatic Cancer Action Network and published by the Cancer Research Journal, early detection for Pancreatic Cancer is particularly important because it is known as the "silent killer", by the time symptoms appear it is usually too late and is known to have a very low survival rate of 7% over 5 years.

6 May 2015

Acacia Pharma reports positive results from APD403 Phase 2 study in CINV

Acacia Pharma Ltd, a specialty pharmaceutical company developing supportive care products for post-surgical and cancer patients in the US and international markets, announces positive results from its Phase 2 study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).

6 May 2015

Exalenz Bioscience investigates clinical utility of BreathID test to diagnose NASH

Exalenz Bioscience, a leader in developing and marketing of non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced the initiation of a clinical study evaluating the potential of its BreathID test to diagnose nonalcoholic steatohepatitis (NASH).

6 May 2015

Study sheds light on long-hidden link between chronic high blood sugar and disruption of mitochondria

Scientists at Johns Hopkins say they've discovered a cause-and-effect link between chronic high blood sugar and disruption of mitochondria, the powerhouses that create the metabolic energy that runs living cells. The discovery, reported online in Proceedings of the National Academy of Sciences on April 27, sheds light on a long-hidden connection and, they say, could eventually lead to new ways of preventing and treating diabetes.

6 May 2015

Common electric brain stimulation has significant detrimental effect on IQ scores

Using a weak electric current in an attempt to boost brainpower or treat conditions has become popular among scientists and do-it-yourselfers, but a new University of North Carolina School of Medicine study shows that using the most common form of electric brain stimulation had a statistically significant detrimental effect on IQ scores.

6 May 2015

RIT's Behnaz Ghoraani awarded NIH grant to develop new atrial fibrillation solution

Behnaz Ghoraani, engineering faculty at Rochester Institute of Technology, was recently awarded a $456,000 grant from the National Institutes for Health for the project "Catheter guidance algorithm for identification of atrial fibrillation ablation."

6 May 2015

Medical Condition News

NanoPass signs license agreement for supply of MicronJet600 device to Circassia

JDRF, Lilly partner to make life better for people with type 1 diabetes

Elekta striving to build radiation therapy infrastructures and save lives of cancer patients in Africa

CCM and MD Anderson partner to improve cancer care in China, Singapore

Researchers compile new genomic interactions catalogue

AbbVie's venetoclax granted FDA Breakthrough Therapy Designation for CLL patients with 17p deletion

Partners congratulate researchers on forming new biotechnology company

Luxembourg biologists provide complete image of human 'miRNome' in blood samples

Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of gastric cancers

Weston Park Hospital offers two cutting-edge treatments for rare cancer tumours, prostate cancer

First patient receives new 'resistance-busting' experimental skin cancer drug

Scientists identify mechanism that explains how some stem cells get new identity

Automated PoCyton cytometer effective for counting cancer cells

Diabetic neuropathy highly prevalent among diabetic patients in Romania

Zetz Family PCRF, Johns Hopkins Medicine partner for pancreatic cancer research

Acacia Pharma reports positive results from APD403 Phase 2 study in CINV

Exalenz Bioscience investigates clinical utility of BreathID test to diagnose NASH

Study sheds light on long-hidden link between chronic high blood sugar and disruption of mitochondria

Common electric brain stimulation has significant detrimental effect on IQ scores

RIT's Behnaz Ghoraani awarded NIH grant to develop new atrial fibrillation solution

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News